Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A6561
Buy Now

Market Overview:

The 7 major non-small cell lung cancer (NSCLC) markets reached a value of US$ 11.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 23.1 Billion by 2034, exhibiting a growth rate (CAGR) of 6.6% during 2024-2034.

Report Attribute
Key Statistics
Base Year  2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 11.4 Billion
Market Forecast in 2034
US$ 23.1 Billion
Market Growth Rate 2024-2034
6.6%


The Non-Small Cell Lung Cancer (NSCLC) Market has been comprehensively analyzed in IMARC’s new report titled “Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast”. Non-small cell lung cancer (NSCLC) is a form of oncology disease in which malignant (cancer) cells form in the lung tissues. It can be categorized into squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Other less-known types of non-small cell lung cancer are adenosquamous carcinoma, sarcomatoid carcinoma, salivary gland carcinoma, carcinoid tumor, and unclassified carcinoma. The major symptoms of non-small lung cancer are continuous cough and shortness of breath. In addition to this, chest discomfort or pain, wheezing, blood in sputum, hoarseness, loss of appetite, weight loss, tiredness, and trouble swallowing are the other common symptoms experienced by patients suffering from non-small cell lung cancer (NSCLC). Non-small cell lung cancer is diagnosed and staged using pulmonary examination tests, which are carried out simultaneously. Physical exams, laboratory tests, chest X-rays, CT scans (CAT scans), sputum cytology, and thoracentesis are the common tests and procedures performed to detect non-small cell lung cancer (NSCLC) among patients. Some treatment options for non-small cell lung cancer (NSCLC) are bronchoscopy, thoracoscopy, mediastinoscopy, lymph node biopsy, etc.

Non-Small Cell Lung Cancer (NSCLC) Market

The increasing incidences of respiratory disorders on account of the deteriorating air quality, unhealthy lifestyle preferences, and high smoking rates among the masses are primarily driving the non-small cell lung cancer market. In addition to this, the expanding geriatric population, who are more prone to develop acute respiratory illnesses, is also bolstering the market growth. Moreover, the rising demand for targeted therapies owing to improved patient outcomes is further creating a positive outlook for the market. These treatments aim to selectively target cancer cells by adhering to or obstructing targets that are present on their surfaces. Besides this, the widespread adoption of radiation therapy combined with chemotherapy to treat patients with locally advanced unresectable disease is also acting as a significant growth-inducing factor. Several other factors, including the continuous upgradation of the existing healthcare infrastructures and the introduction of advanced variants with enhanced efficacy and effectiveness of treatment, are expected to drive the non-small cell lung cancer market in the coming years.

IMARC Group’s new report "Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Non-Small Cell Lung Cancer (NSCLC) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Non-Small Cell Lung Cancer (NSCLC) market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Non-Small Cell Lung Cancer (NSCLC) across the seven major markets. According to the report the United States has the largest patient pool for Non-Small Cell Lung Cancer (NSCLC) and also represents the largest market for Non-Small Cell Lung Cancer (NSCLC) treatment. Furthermore, the current Non-Small Cell Lung Cancer (NSCLC) treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non-Small Cell Lung Cancer (NSCLC) market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034


Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Non-Small Cell Lung Cancer (NSCLC) Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Non-Small Cell Lung Cancer (NSCLC) Market
  • Sales of Various Drugs Across the Non-Small Cell Lung Cancer (NSCLC) Market
  • Reimbursement Scenario in the Non-Small Cell Lung Cancer (NSCLC) Market
  • In-Market and Pipeline Drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Non-Small Cell Lung Cancer (NSCLC) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Rozlytrek (Entrectinib) Hoffmann-La Roche
Imfinzi (Durvalumab) AstraZeneca
Opdivo (Nivolumab) Bristol-Myers Squibb
Keytruda (Pembrolizumab) Merck
Vizimpro (Dacomitinib) Pfizer
EGF816 (Nazartinib) Novartis Pharmaceuticals
Telisotuzumab Vedotin AbbVie
SAR408701 (Tusamitamab Ravtansine) Sanofi
ACZ885 (Canakinumab) Novartis
BAVENCIO (Avelumab) Merck/Pfizer


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the Non-Small Cell Lung Cancer (NSCLC) market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
  • What was the country-wise size of the Non-Small Cell Lung Cancer (NSCLC) market across the seven major markets in 2023 and how will it look like in 2034?
  • What is the growth rate of the Non-Small Cell Lung Cancer (NSCLC) market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Non-Small Cell Lung Cancer (NSCLC) market?
     

Epidemiology Insights

  • What is the size of the Non-Small Cell Lung Cancer (NSCLC) patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) of Non-Small Cell Lung Cancer (NSCLC) across the seven major markets?
  • What are the key factors driving the epidemiological trend of Non-Small Cell Lung Cancer (NSCLC)?
  • What will be the growth rate of Non-Small Cell Lung Cancer (NSCLC) patients across the seven major markets?
     

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed Non-Small Cell Lung Cancer (NSCLC) drugs and what are their market performance?
  • What are the key pipeline Non-Small Cell Lung Cancer (NSCLC) drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed Non-Small Cell Lung Cancer (NSCLC) drugs and what are their efficacies?
  • How safe are the late-stage pipeline Non-Small Cell Lung Cancer (NSCLC) drugs and what are their efficacies?
  • What are the current treatment guidelines for Non-Small Cell Lung Cancer (NSCLC) drugs across the seven major markets?
  • Who are the key companies in the Non-Small Cell Lung Cancer (NSCLC) market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non-Small Cell Lung Cancer (NSCLC) market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More